Less than two months after GlaxoSmithKline pledged to cap out-of-pocket costs, Sen. Maggie Hassan (D-N.H.) is accusing the ...
Drug manufacturing giant GSK is subverting its pledge to lower the price of its brand-name inhaler products, a key Democratic ...
Toward the end of March, GSK followed in the footsteps of Boehringer Ingelheim and AstraZeneca when it pledged to cap out-of-pocket costs for its inhalers at $35 per month by Jan. 1, 2025. Aside from ...
When PBMs refuse to cover the cheaper generic, patients are left on the hook for the full cost. Insurers and employers hire ...
GSK pledged March 20 to cap out-of-pocket costs for its ... companies for setting high inhaler prices that they say are unreasonable; for instance, AstraZeneca in January charged about $650 ...
When I read the news that three out of four manufacturers of asthma and COPD inhalers have decided to cap the price to the ...
The move targets over 300 listings for 20 branded products from companies such as AstraZeneca, Novo Nordisk, and GSK that the ...
The US Federal Trade Commission has accused 10 multinational pharmaceutical manufacturers, including GSK, of blocking the ...
Sanders and other lawmakers in January criticized four makers of inhalers sold in the U.S. — AstraZeneca, Boehringer ... In March, three of the four companies decided to cap inhaler costs at $35 each.
Boehringer Ingelheim, GSK, Novartis, Teva, and Covis Pharma have been taken to task for asthma and COPD inhalers, while ...